Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
The go-ahead for Alnylam Pharmaceuticals–partnered Livsayis marks Regeneron’s second new modality this year after the company secured approval for hearing loss gene therapy Otarmeni in April.
comments(0)
5-min edit window · permanent after that